磷酸化tau生物标志物与淀粉样蛋白正电子发射断层扫描及tau正电子发射断层扫描的关联
这项横断面研究纳入两个观察性队列共609名参与者,评估脑脊液和血浆磷酸化tau(p-tau)生物标志物与淀粉样蛋白PET及tau PET的关联。结果显示所有p-tau标志物与淀粉样蛋白PET的关联均显著强于与tau PET的关联,提示p-tau异常作为AD发病早期事件与β-淀粉样蛋白积累相关。
要点
- 脑脊液p-tau181、p-tau217、p-tau231、p-tau235与淀粉样蛋白PET的关联均显著强于与tau PET的关联。
- 血浆p-tau181、p-tau217、p-tau231及脑脊液p-tau181在独立队列中重复了上述结果。
- 作者认为需在A/T/(N)框架下谨慎解读p-tau生物标志物。
核心结论
- 这项两观察性队列的横断面研究提示,p-tau异常作为AD发病早期事件与β-淀粉样蛋白积累相关,并强调需在淀粉样蛋白/tau/神经退行性变(A/T/(N))框架下谨慎解读p-tau生物标志物。
研究设计与样本
- 横断面研究,纳入两个观察性队列:TRIAD研究(数据收集于2017年10月至2021年8月,单中心)和ADNI(数据收集于2015年9月至2019年11月,多中心)。
- 从TRIAD衍生两个独立子样本:第一个子样本接受脑脊液p-tau(p-tau181、p-tau217、p-tau231、p-tau235)、[18F]AZD4694淀粉样蛋白PET和[18F]MK6240 tau PET评估;第二个子样本接受血浆p-tau(p-tau181、p-tau217、p-tau231)、[18F]AZD4694淀粉样蛋白PET和[18F]MK6240 tau PET评估。
- ADNI独立队列接受脑脊液p-tau181、[18F]florbetapir PET和[18F]flortaucipir PET评估。
- 纳入标准为p-tau与PET生物标志物评估在9个月内完成;排除标准为头部外伤史或磁共振成像/PET安全禁忌证;无符合条件者被排除。
- 共纳入609名参与者(平均[SD]年龄66.9[13.6]岁;女性347名[57%];男性262名[43%])。
主要发现
- 脑脊液所有4个磷酸化位点评估中,p-tau与淀粉样蛋白PET值的关联均显著强于与tau PET值的关联:p-tau181差异13%(95%CI 3%-22%;P=.006);p-tau217差异11%(95%CI 3%-20%;P=.003);p-tau231差异15%(95%CI 5%-22%;P<.001);p-tau235差异9%(95%CI 1%-19%;P=.02)。
- 独立队列中重复了上述结果:血浆p-tau181差异11%(95%CI 1%-22%;P=.02);血浆p-tau217差异9%(95%CI 1%-19%;P=.02);血浆p-tau231差异13%(95%CI 3%-24%;P=.009);脑脊液p-tau181差异9%(95%CI 1%-21%;P=.02)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised questions about their preferential association with the hallmark pathologies of Alzheimer disease (AD): amyloid-β plaques and tau neurofibrillary tangles. OBJECTIVE: To determine whether cerebrospinal fluid (CSF) and plasma p-tau biomarkers preferentially reflect cerebral β-amyloidosis or neurofibrillary tangle aggregation measured with positron emission tomography (PET). DESIGN, SETTING, AND PARTICIPANTS: This was a cross-sectional study of 2 observational cohorts: the Translational Biomarkers in Aging and Dementia (TRIAD) study, with data collected between October 2017 and August 2021, and the Alzheimer's Disease Neuroimaging Initiative (ADNI), with data collected between September 2015 and November 2019. TRIAD was a single-center study, and ADNI was a multicenter study. Two independent subsamples were derived from TRIAD. The first TRIAD subsample comprised individuals assessed with CSF p-tau (p-tau181, p-tau217, p-tau231, p-tau235), [18F]AZD4694 amyloid PET, and [18F]MK6240 tau PET. The second TRIAD subsample included individuals assessed with plasma p-tau (p-tau181, p-tau217, p-tau231), [18F]AZD4694 amyloid PET, and [18F]MK6240 tau PET. An independent cohort from ADNI comprised individuals assessed with CSF p-tau181, [18F]florbetapir PET, and [18F]flortaucipir PET. Participants were included based on the availability of p-tau and PET biomarker assessments collected within 9 months of each other. Exclusion criteria were a history of head trauma or magnetic resonance imaging/PET safety contraindications. No participants who met eligibility criteria were excluded. EXPOSURES: Amyloid PET, tau PET, and CSF and plasma assessments of p-tau measured with single molecule array (Simoa) assay or enzyme-linked immunosorbent assay. MAIN OUTCOMES AND MEASURES: Associations between p-tau biomarkers with amyloid PET and tau PET. RESULTS: A total of 609 participants (mean [SD] age, 66.9 [13.6] years; 347 female [57%]; 262 male [43%]) were included in the study. For all 4 phosphorylation sites assessed in CSF, p-tau was significantly more closely associated with amyloid-PET values than tau-PET values (p-tau181 difference, 13%; 95% CI, 3%-22%; P = .006; p-tau217 difference, 11%; 95% CI, 3%-20%; P = .003; p-tau231 difference, 15%; 95% CI, 5%-22%; P < .001; p-tau235 difference, 9%; 95% CI, 1%-19%; P = .02) . These results were replicated with plasma p-tau181 (difference, 11%; 95% CI, 1%-22%; P = .02), p-tau217 (difference, 9%; 95% CI, 1%-19%; P = .02), p-tau231 (difference, 13%; 95% CI, 3%-24%; P = .009), and CSF p-tau181 (difference, 9%; 95% CI, 1%-21%; P = .02) in independent cohorts. CONCLUSIONS AND RELEVANCE: Results of this cross-sectional study of 2 observational cohorts suggest that the p-tau abnormality as an early event in AD pathogenesis was associated with amyloid-β accumulation and highlights the need for careful interpretation of p-tau biomarkers in the context of the amyloid/tau/neurodegeneration, or A/T/(N), framework.
引用
- Therriault J, Vermeiren M, Servaes S, et al. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography. JAMA Neurol. 2023. PMID: 36508198. doi:10.1001/jamaneurol.2022.4485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。